{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,29]],"date-time":"2026-03-29T06:18:43Z","timestamp":1774765123593,"version":"3.50.1"},"reference-count":119,"publisher":"Georg Thieme Verlag KG","issue":"01","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Semin Liver Dis"],"published-print":{"date-parts":[[2023,2]]},"abstract":"<jats:p>Alcohol-associated liver disease is a leading cause of mortality and morbidity worldwide. Patients with alcohol-associated liver disease are often diagnosed at advanced stage and disease spectrum including alcoholic hepatitis, a severe manifestation with a high short-term mortality. Corticosteroid, recommended first-line treatment for patients with alcoholic hepatitis, is a very suboptimal treatment. Although the use of early liver transplantation has increased with consistent benefit in select patients with alcoholic hepatitis, its use remains heterogeneous worldwide due to lack of uniform selection criteria. Over the last decade, several therapeutic targets have evolved of promise with ongoing clinical trials in patients with cirrhosis and alcoholic hepatitis. Even with availability of effective medical therapies for alcohol-associated liver disease, long-term outcome depends on abstinence from alcohol use in any spectrum of alcohol-associated liver disease. However, alcohol use disorder treatment remains underutilized due to several barriers even in patients with advanced disease. There is an urgent unmet need to implement and promote integrated multidisciplinary care model with hepatologists and addiction experts to provide comprehensive management for these patients. In this review, we will discuss newer therapies targeting liver disease and therapies targeting alcohol use disorder in patients with alcohol-associated liver disease.<\/jats:p>","DOI":"10.1055\/s-0042-1759614","type":"journal-article","created":{"date-parts":[[2022,12,26]],"date-time":"2022-12-26T23:40:11Z","timestamp":1672098011000},"page":"060-076","source":"Crossref","is-referenced-by-count":10,"title":["Therapeutic Pipeline in Alcohol-Associated Liver Disease"],"prefix":"10.1055","volume":"43","author":[{"given":"Nimish","family":"Thakral","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, University of Kentucky, Lexington, Kentucky"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sasha","family":"Deutsch-Link","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of North Carolina at Chapel Hill, North Carolina"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashwani K.","family":"Singal","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of South Dakota Sanford School of Medicine, Sioux Falls, South Dakota"},{"name":"Division of Transplant Hepatology, Avera Transplant Institute, Sioux Falls, South Dakota"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2022,12,26]]},"reference":[{"issue":"01","key":"ref1","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.jhep.2018.09.014","article-title":"Burden of liver diseases in the world","volume":"70","author":"S K Asrani","year":"2019","journal-title":"J Hepatol"},{"issue":"02","key":"ref2","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1001\/jama.2021.7683","article-title":"Diagnosis and treatment of alcohol-associated liver disease: a review","volume":"326","author":"A K Singal","year":"2021","journal-title":"JAMA"},{"issue":"03","key":"ref3","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.cld.2016.02.002","article-title":"Spectrum of alcoholic liver disease","volume":"20","author":"K R Chacko","year":"2016","journal-title":"Clin Liver Dis"},{"issue":"374","key":"ref5","first-page":"1","article-title":"Heavy drinking among U.S. adults, 2018","author":"P Boersma","year":"2020","journal-title":"NCHS Data Brief"},{"issue":"09","key":"ref6","doi-asserted-by":"crossref","first-page":"e2022942","DOI":"10.1001\/jamanetworkopen.2020.22942","article-title":"Changes in adult alcohol use and consequences during the COVID-19 pandemic in the US","volume":"3","author":"M S Pollard","year":"2020","journal-title":"JAMA Netw Open"},{"issue":"05","key":"ref7","doi-asserted-by":"crossref","first-page":"e1170","DOI":"10.1016\/j.cgh.2021.10.030","article-title":"Impact of the COVID-19 pandemic on hospitalizations for alcoholic hepatitis or cirrhosis in Alberta, Canada","volume":"20","author":"A A Shaheen","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"06","key":"ref8","doi-asserted-by":"crossref","first-page":"3316","DOI":"10.1002\/hep.32067","article-title":"Impact of COVID-19 pandemic on liver transplantation and alcohol-associated liver disease in the USA","volume":"74","author":"G Cholankeril","year":"2021","journal-title":"Hepatology"},{"issue":"06","key":"ref9","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1002\/hep.32272","article-title":"Effect of increased alcohol consumption during COVID-19 pandemic on alcohol-associated liver disease: a modeling study","volume":"75","author":"J Julien","year":"2022","journal-title":"Hepatology"},{"issue":"07","key":"ref10","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1111\/acer.13108","article-title":"Diagnosis and treatment of alcoholic hepatitis: a systematic review","volume":"40","author":"A K Singal","year":"2016","journal-title":"Alcohol Clin Exp Res"},{"issue":"01","key":"ref11","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41575-021-00527-0","article-title":"Management of alcohol use disorder in patients with cirrhosis in the setting of liver transplantation","volume":"19","author":"J P Arab","year":"2022","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"ref12","volume-title":"American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders","author":"M J Asken","year":"2013"},{"issue":"16","key":"ref13","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1001\/archinte.158.16.1789","article-title":"The AUDIT alcohol consumption questions (AUDIT-C): an effective brief screening test for problem drinking. Ambulatory Care Quality Improvement Project (ACQUIP). Alcohol Use Disorders Identification Test","volume":"158","author":"K Bush","year":"1998","journal-title":"Arch Intern Med"},{"issue":"07","key":"ref14","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1111\/j.1530-0277.2007.00403.x","article-title":"AUDIT-C as a brief screen for alcohol misuse in primary care","volume":"31","author":"K A Bradley","year":"2007","journal-title":"Alcohol Clin Exp Res"},{"issue":"06","key":"ref15","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1007\/s11606-008-0594-0","article-title":"Effectiveness of the AUDIT-C as a screening test for alcohol misuse in three race\/ethnic groups","volume":"23","author":"D Frank","year":"2008","journal-title":"J Gen Intern Med"},{"issue":"11","key":"ref16","doi-asserted-by":"crossref","first-page":"2320","DOI":"10.1016\/j.cgh.2019.01.026","article-title":"Alcohol-related liver disease is rarely detected at early stages compared with liver diseases of other etiologies worldwide","volume":"17","author":"N D Shah","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"02","key":"ref17","first-page":"183","article-title":"Alcoholic liver disease presents at advanced stage and progresses faster compared to non-alcoholic fatty liver disease","volume":"15","author":"M Shoreibah","year":"2016","journal-title":"Ann Hepatol"},{"issue":"07","key":"ref19","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1176\/appi.ps.201000553","article-title":"Pharmacotherapy of alcohol use disorders by the Veterans Health Administration: patterns of receipt and persistence","volume":"63","author":"A HS Harris","year":"2012","journal-title":"Psychiatr Serv"},{"issue":"05","key":"ref20","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1002\/hep.29240","article-title":"Main drivers of outcome differ between short term and long term in severe alcoholic hepatitis: a prospective study","volume":"66","author":"A Louvet","year":"2017","journal-title":"Hepatology"},{"issue":"06","key":"ref21","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1002\/hep.29338","article-title":"Alcohol abstinence in patients surviving an episode of alcoholic hepatitis: prediction and impact on long-term survival","volume":"66","author":"J Altamirano","year":"2017","journal-title":"Hepatology"},{"issue":"05","key":"ref22","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1093\/alcalc\/agac015","article-title":"Identifying alcohol use disorder in patients with cirrhosis reduces 30-days readmission rate","volume":"57","author":"A K Singal","year":"2022","journal-title":"Alcohol Alcohol"},{"issue":"03","key":"ref23","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/j.jhep.2016.11.011","article-title":"Histological parameters and alcohol abstinence determine long-term prognosis in patients with alcoholic liver disease","volume":"66","author":"C Lackner","year":"2017","journal-title":"J Hepatol"},{"issue":"12","key":"ref24","doi-asserted-by":"crossref","first-page":"2080","DOI":"10.1002\/hep4.1776","article-title":"Associations between alcohol use and liver-related outcomes in a large national cohort of patients with cirrhosis","volume":"5","author":"M M Pearson","year":"2021","journal-title":"Hepatol Commun"},{"issue":"03","key":"ref25","doi-asserted-by":"crossref","first-page":"470","DOI":"10.5604\/01.3001.0011.7391","article-title":"Alcohol consumption influences clinical outcome in patients admitted to a referral center for liver disease","volume":"17","author":"S GRD Santos","year":"2018","journal-title":"Ann Hepatol"},{"issue":"02","key":"ref26","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.cgh.2019.04.048","article-title":"Alcohol rehabilitation within 30 days of hospital discharge is associated with reduced readmission, relapse, and death in patients with alcoholic hepatitis","volume":"18","author":"T B Peeraphatdit","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"05","key":"ref28","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1097\/MEG.0000000000002304","article-title":"Acamprosate may be safer than baclofen for the treatment of alcohol use disorder in patients with cirrhosis: a first description of use in real-world clinical practice","volume":"34","author":"L D Tyson","year":"2022","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"05","key":"ref29","doi-asserted-by":"crossref","first-page":"e2213014","DOI":"10.1001\/jamanetworkopen.2022.13014","article-title":"Incidence and progression of alcohol-associated liver disease after medical therapy for alcohol use disorder","volume":"5","author":"A GL Vannier","year":"2022","journal-title":"JAMA Netw Open"},{"issue":"04","key":"ref30","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s40471-015-0053-5","article-title":"The active comparator, new user study design in pharmacoepidemiology: historical foundations and contemporary application","volume":"2","author":"J L Lund","year":"2015","journal-title":"Curr Epidemiol Rep"},{"issue":"02","key":"ref31","doi-asserted-by":"crossref","first-page":"e87366","DOI":"10.1371\/journal.pone.0087366","article-title":"Disulfiram efficacy in the treatment of alcohol dependence: a meta-analysis","volume":"9","author":"M D Skinner","year":"2014","journal-title":"PLoS One"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1016\/S0140-6736(07)61814-5","article-title":"Effectiveness and safety of baclofen for maintenance of alcohol abstinence in alcohol-dependent patients with liver cirrhosis: randomised, double-blind controlled study","volume":"370","author":"G Addolorato","year":"2007","journal-title":"Lancet"},{"issue":"04","key":"ref34","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/j.addbeh.2011.12.010","article-title":"Baclofen promotes alcohol abstinence in alcohol dependent cirrhotic patients with hepatitis C virus (HCV) infection","volume":"37","author":"L Leggio","year":"2012","journal-title":"Addict Behav"},{"issue":"06","key":"ref35","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1192\/bjp.2018.13","article-title":"Baclofen in the treatment of alcohol dependence with or without liver disease: multisite, randomised, double-blind, placebo-controlled trial","volume":"212","author":"K C Morley","year":"2018","journal-title":"Br J Psychiatry"},{"issue":"09","key":"ref36","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1111\/add.14655","article-title":"A meta-analysis of the efficacy of gabapentin for treating alcohol use disorder","volume":"114","author":"H R Kranzler","year":"2019","journal-title":"Addiction"},{"issue":"06","key":"ref37","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1111\/acer.12411","article-title":"A meta-analysis of topiramate's effects for individuals with alcohol use disorders","volume":"38","author":"J C Blodgett","year":"2014","journal-title":"Alcohol Clin Exp Res"},{"issue":"02","key":"ref38","doi-asserted-by":"crossref","first-page":"19r12924","DOI":"10.4088\/JCP.19r12924","article-title":"The impact of varenicline on alcohol consumption in subjects with alcohol use disorders: systematic review and meta-analyses","volume":"81","author":"K D Gandhi","year":"2020","journal-title":"J Clin Psychiatry"},{"issue":"02","key":"ref39","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1001\/jamapsychiatry.2017.3544","article-title":"Effect of varenicline combined with medical management on alcohol use disorder with comorbid cigarette smoking: a randomized clinical trial","volume":"75","author":"S S O'Malley","year":"2018","journal-title":"JAMA Psychiatry"},{"issue":"18","key":"ref40","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1001\/jama.2014.3628","article-title":"Pharmacotherapy for adults with alcohol use disorders in outpatient settings: a systematic review and meta-analysis","volume":"311","author":"D E Jonas","year":"2014","journal-title":"JAMA"},{"issue":"03","key":"ref41","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/S0168-8278(97)80355-8","article-title":"Effect of liver cirrhosis on the systemic availability of naltrexone in humans","volume":"27","author":"M Bertolotti","year":"1997","journal-title":"J Hepatol"},{"issue":"04","key":"ref42","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1053\/gast.1997.v113.pm9322521","article-title":"Oral naltrexone treatment for cholestatic pruritus: a double-blind, placebo-controlled study","volume":"113","author":"F H Wolfhagen","year":"1997","journal-title":"Gastroenterology"},{"issue":"01","key":"ref44","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1002\/hep.30866","article-title":"Diagnosis and treatment of alcohol-associated liver diseases: 2019 practice guidance from the American Association for the Study of Liver Diseases","volume":"71","author":"D W Crabb","year":"2020","journal-title":"Hepatology"},{"issue":"02","key":"ref45","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/ajg.2017.469","article-title":"ACG Clinical Guideline: alcoholic liver disease","volume":"113","author":"A K Singal","year":"2018","journal-title":"Am J Gastroenterol"},{"issue":"01","key":"ref46","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1176\/appi.ajp.2017.1750101","article-title":"The American Psychiatric Association Practice Guideline for the pharmacological treatment of patients with alcohol use disorder","volume":"175","author":"V I Reus","year":"2018","journal-title":"Am J Psychiatry"},{"issue":"02","key":"ref47","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/S2468-1253(21)00191-6","article-title":"Barriers to the management of alcohol use disorder and alcohol-associated liver disease: strategies to implement integrated care models","volume":"7","author":"A F DiMartini","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"ref48","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.drugalcdep.2016.01.005","article-title":"A 10-year study of factors associated with alcohol treatment use and non-use in a U.S. population sample","volume":"160","author":"K G Chartier","year":"2016","journal-title":"Drug Alcohol Depend"},{"issue":"01","key":"ref49","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s13011-015-0028-z","article-title":"Alcohol use disorder severity and reported reasons not to seek treatment: a cross-sectional study in European primary care practices","volume":"10","author":"C Probst","year":"2015","journal-title":"Subst Abuse Treat Prev Policy"},{"issue":"11","key":"ref50","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1176\/appi.ps.201400160","article-title":"Perceived barriers to treatment for alcohol problems: a latent class analysis","volume":"66","author":"M S Schuler","year":"2015","journal-title":"Psychiatr Serv"},{"issue":"02","key":"ref51","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/S2468-1253(21)00191-6","article-title":"Barriers to the management of alcohol use disorder and alcohol-associated liver disease: strategies to implement integrated care models","volume":"7","author":"A F DiMartini","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"11","key":"ref52","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1016\/j.cgh.2020.10.026","article-title":"Provider attitudes and practices for alcohol screening, treatment, and education in patients with liver disease: a survey from the American Association for the Study of Liver Diseases Alcohol-Associated Liver Disease Special Interest Group","volume":"19","author":"G Y Im","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"06","key":"ref53","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1053\/j.gastro.2021.08.004","article-title":"Results of early transplantation for alcohol-related cirrhosis: integrated addiction treatment with low rate of relapse","volume":"161","author":"L Carrique","year":"2021","journal-title":"Gastroenterology"},{"issue":"01","key":"ref54","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.transproceed.2018.02.212","article-title":"Impact of a multidisciplinary team on alcohol recidivism and survival after liver transplant for alcoholic disease","volume":"51","author":"P Magistri","year":"2019","journal-title":"Transplant Proc"},{"issue":"03","key":"ref55","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.cld.2016.02.010","article-title":"Nutrition and alcoholic liver disease: effects of alcoholism on nutrition, effects of nutrition on alcoholic liver disease, and nutritional therapies for alcoholic liver disease","volume":"20","author":"S Dasarathy","year":"2016","journal-title":"Clin Liver Dis"},{"issue":"04","key":"ref57","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/j.cgh.2013.06.013","article-title":"Alcoholic hepatitis: current challenges and future directions","volume":"12","author":"A K Singal","year":"2014","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"04","key":"ref58","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1053\/j.gastro.2016.02.042","article-title":"Standard definitions and common data elements for clinical trials in patients with alcoholic hepatitis: recommendation from the NIAAA Alcoholic Hepatitis Consortia","volume":"150","author":"D W Crabb","year":"2016","journal-title":"Gastroenterology"},{"issue":"02","key":"ref59","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/ajg.2017.469","article-title":"ACG Clinical Guideline: alcoholic liver disease","volume":"113","author":"A K Singal","year":"2018","journal-title":"Off J Am Coll Gastroenterol"},{"issue":"01","key":"ref60","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.jhep.2018.03.018","article-title":"EASL Clinical Practice Guidelines: management of alcohol-related liver disease","volume":"69","author":"European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu","year":"2018","journal-title":"J Hepatol"},{"issue":"08","key":"ref62","doi-asserted-by":"crossref","first-page":"205","DOI":"10.4254\/wjh.v3.i8.205","article-title":"Corticosteroids and pentoxifylline for the treatment of alcoholic hepatitis: current status","volume":"3","author":"A K Singal","year":"2011","journal-title":"World J Hepatol"},{"issue":"04","key":"ref63","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1053\/j.gastro.2015.06.006","article-title":"Comparative effectiveness of pharmacological interventions for severe alcoholic hepatitis: a systematic review and network meta-analysis","volume":"149","author":"S Singh","year":"2015","journal-title":"Gastroenterology"},{"issue":"02","key":"ref64","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1053\/j.gastro.2018.05.011","article-title":"Corticosteroids reduce risk of death within 28 days for patients with severe alcoholic hepatitis, compared with pentoxifylline or placebo-a meta-analysis of individual data from controlled trials","volume":"155","author":"A Louvet","year":"2018","journal-title":"Gastroenterology"},{"issue":"19","key":"ref65","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1056\/NEJMoa1105703","article-title":"Early liver transplantation for severe alcoholic hepatitis","volume":"365","author":"P Mathurin","year":"2011","journal-title":"N Engl J Med"},{"issue":"02","key":"ref66","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1053\/j.gastro.2009.04.062","article-title":"Infection in patients with severe alcoholic hepatitis treated with steroids: early response to therapy is the key factor","volume":"137","author":"A Louvet","year":"2009","journal-title":"Gastroenterology"},{"issue":"06","key":"ref67","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1002\/hep.21607","article-title":"The Lille model: a new tool for therapeutic strategy in patients with severe alcoholic hepatitis treated with steroids","volume":"45","author":"A Louvet","year":"2007","journal-title":"Hepatology"},{"issue":"05","key":"ref68","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1053\/j.gastro.2016.12.019","article-title":"In patients with severe alcoholic hepatitis, prednisolone increases susceptibility to infection and infection-related mortality, and is associated with high circulating levels of bacterial DNA","volume":"152","author":"N Vergis","year":"2017","journal-title":"Gastroenterology"},{"issue":"05","key":"ref69","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1053\/j.gastro.2017.02.030","article-title":"Infection in severe alcoholic hepatitis: yet another piece in the puzzle","volume":"152","author":"A K Singal","year":"2017","journal-title":"Gastroenterology"},{"key":"ref70","volume-title":"Cellular Bioenergetics: A Promising Biomarker in Management of Patients with Alcoholic Liver Disease","author":"A K Singal","edition":"Vol 66"},{"issue":"01","key":"ref71","doi-asserted-by":"crossref","first-page":"49","DOI":"10.3727\/105221618X15325235888914","article-title":"Cellular abnormalities and emerging biomarkers in alcohol-associated liver disease","volume":"19","author":"A K Singal","year":"2018","journal-title":"Gene Expr"},{"issue":"01","key":"ref72","doi-asserted-by":"crossref","first-page":"6816","DOI":"10.1038\/s41598-017-07161-4","article-title":"Pre-therapy liver transcriptome landscape in Indian and French patients with severe alcoholic hepatitis and steroid responsiveness","volume":"7","author":"S Sharma","year":"2017","journal-title":"Sci Rep"},{"issue":"03","key":"ref73","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1016\/j.jhep.2008.10.028","article-title":"Evidence that chronic alcohol exposure promotes intestinal oxidative stress, intestinal hyperpermeability and endotoxemia prior to development of alcoholic steatohepatitis in rats","volume":"50","author":"A Keshavarzian","year":"2009","journal-title":"J Hepatol"},{"key":"ref74","doi-asserted-by":"crossref","first-page":"S19","DOI":"10.1016\/j.jceh.2015.07.037","article-title":"Corticosteroids and bovine colostrum in treatment of alcoholic hepatitis \u2018in extremis\u2019: a pilot study","volume":"5","author":"S Sidhu","year":"2015","journal-title":"J Clin Exp Hepatol"},{"issue":"04","key":"ref75","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/j.cld.2012.08.009","article-title":"Nutrition in alcoholic liver disease","volume":"16","author":"A K Singal","year":"2012","journal-title":"Clin Liver Dis"},{"issue":"09","key":"ref76","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1203\/00006450-198509000-00020","article-title":"The effects of severe zinc deficiency on intestinal permeability: an ultrastructural study","volume":"19","author":"J R Moran","year":"1985","journal-title":"Pediatr Res"},{"issue":"10","key":"ref77","doi-asserted-by":"crossref","first-page":"e76522","DOI":"10.1371\/journal.pone.0076522","article-title":"Dietary zinc deficiency exaggerates ethanol-induced liver injury in mice: involvement of intrahepatic and extrahepatic factors","volume":"8","author":"W Zhong","year":"2013","journal-title":"PLoS One"},{"issue":"09","key":"ref78","doi-asserted-by":"crossref","first-page":"G757","DOI":"10.1152\/ajpgi.00442.2014","article-title":"Zinc deficiency mediates alcohol-induced apoptotic cell death in the liver of rats through activating ER and mitochondrial cell death pathways","volume":"308","author":"Q Sun","year":"2015","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"issue":"06","key":"ref79","doi-asserted-by":"crossref","first-page":"1444A","DOI":"10.1002\/hep.30353","article-title":"IL-1 receptor antagonist in combination with pentoxifylline and zinc for severe alcoholic hepatitis. A multicenter randomized double-bind placebo-controlled clinical trial","volume":"68","year":"2018","journal-title":"Hepatology"},{"issue":"01","key":"ref80","doi-asserted-by":"crossref","first-page":"e53028","DOI":"10.1371\/journal.pone.0053028","article-title":"Metagenomic analyses of alcohol induced pathogenic alterations in the intestinal microbiome and the effect of Lactobacillus rhamnosus GG treatment","volume":"8","author":"L Bull-Otterson","year":"2013","journal-title":"PLoS One"},{"issue":"05","key":"ref81","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1136\/gutjnl-2015-310585","article-title":"Intestinal microbiota contributes to individual susceptibility to alcoholic liver disease","volume":"65","author":"M Llopis","year":"2016","journal-title":"Gut"},{"issue":"04","key":"ref82","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.cgh.2016.10.029","article-title":"Healthy donor fecal microbiota transplantation in steroid-ineligible severe alcoholic hepatitis: a pilot study","volume":"15","author":"C A Philips","year":"2017","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"03","key":"ref83","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s12664-018-0859-4","article-title":"Corticosteroids, nutrition, pentoxifylline, or fecal microbiota transplantation for severe alcoholic hepatitis","volume":"37","author":"C A Philips","year":"2018","journal-title":"Indian J Gastroenterol"},{"key":"ref84","first-page":"8A","volume-title":"Three Year Follow-up of Alcohol-Related hepatitis Patients Undergoing Healthy Donor Fecal Transplant: Analysis of Clinical Outcomes, Relapse, Gut Microbiota and Comparisons with Standard Care","author":"C A Philips","year":"2021","edition":"Vol 74"},{"issue":"05","key":"ref85","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1002\/hep.31496","article-title":"A randomized clinical trial of fecal microbiota transplant for alcohol use disorder","volume":"73","author":"J S Bajaj","year":"2021","journal-title":"Hepatology"},{"issue":"04","key":"ref86","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/j.jceh.2022.01.001","article-title":"Long-term outcomes of stool transplant in alcohol-associated hepatitis - analysis of clinical outcomes, relapse, gut microbiota and comparisons with standard care","volume":"12","author":"C A Philips","year":"2022","journal-title":"J Clin Exp Hepatol"},{"key":"ref87","first-page":"S201","volume-title":"Combination of Amoxicillin\/Clavulanate and Prednisolone in Severe Alcoholic Hepatitis: Results of the Randomized Controlled Trial Antibiocor","author":"A Louvet","year":"2021","edition":"Vol 75"},{"issue":"06","key":"ref88","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/j.cell.2010.01.040","article-title":"The inflammasomes","volume":"140","author":"K Schroder","year":"2010","journal-title":"Cell"},{"issue":"04","key":"ref89","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1093\/alcalc\/agx025","article-title":"Gut-liver axis and sterile signals in the development of alcoholic liver disease","volume":"52","author":"G Szabo","year":"2017","journal-title":"Alcohol Alcohol"},{"issue":"01","key":"ref90","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1002\/(SICI)1096-9896(199809)186:1<82::AID-PATH151>3.0.CO;2-D","article-title":"Distinct patterns of chemokine expression are associated with leukocyte recruitment in alcoholic hepatitis and alcoholic cirrhosis","volume":"186","author":"S C Afford","year":"1998","journal-title":"J Pathol"},{"issue":"03","key":"ref91","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/S0168-8278(01)00276-8","article-title":"Polymorphonuclear neutrophils are a source of hepatocyte growth factor in patients with severe alcoholic hepatitis","volume":"36","author":"J Ta\u00efeb","year":"2002","journal-title":"J Hepatol"},{"issue":"01","key":"ref92","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s00109-016-1474-4","article-title":"Interaction between gut microbiota and toll-like receptor: from immunity to metabolism","volume":"95","author":"J HC Yiu","year":"2017","journal-title":"J Mol Med (Berl)"},{"issue":"02","key":"ref93","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1111\/j.1530-0277.2008.00842.x","article-title":"A recent perspective on alcohol, immunity, and host defense","volume":"33","author":"G Szabo","year":"2009","journal-title":"Alcohol Clin Exp Res"},{"issue":"04","key":"ref94","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1038\/nrgastro.2015.35","article-title":"Alcoholic liver disease: mechanisms of injury and targeted treatment","volume":"12","author":"A Louvet","year":"2015","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"08","key":"ref95","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1038\/nrd3800","article-title":"Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases","volume":"11","author":"C A Dinarello","year":"2012","journal-title":"Nat Rev Drug Discov"},{"key":"ref97","first-page":"S35","volume-title":"IL-1Beta Signal Inhibition in Acute Alcoholic Hepatitis: A Multicentre, Randomised, Double-Blind, Placebo-Controlled Phase 2 Trial of Canakinumab Therapy (ISAIAH)","author":"N Vergis","year":"2022","edition":"Vol 7"},{"key":"ref98","first-page":"8A","volume-title":"Selonsertib in Combination with Prednisolone for the Treatment of Severe Alcoholic Hepatitis: A Phase 2 Randomized Controlled Trial","author":"P Mathurin","year":"2018","edition":"Vol 68"},{"issue":"04","key":"ref99","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/j.cgh.2018.06.012","article-title":"Emricasan improves liver function in patients with cirrhosis and high model for end-stage liver disease scores compared with placebo","volume":"17","author":"C T Frenette","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"06","key":"ref100","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1002\/hep.26939","article-title":"Obeticholic acid, a farnesoid X receptor agonist, improves portal hypertension by two distinct pathways in cirrhotic rats","volume":"59","author":"L Verbeke","year":"2014","journal-title":"Hepatology"},{"issue":"03","key":"ref101","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1002\/lt.24986","article-title":"Extracorporeal cellular therapy (ELAD) in severe alcoholic hepatitis: a multinational, prospective, controlled, randomized trial","volume":"24","author":"J Thompson","year":"2018","journal-title":"Liver Transpl"},{"issue":"02","key":"ref102","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1002\/hep.31046","article-title":"An open-label, dose-escalation study to assess the safety and efficacy of IL-22 agonist F-652 in patients with alcohol-associated hepatitis","volume":"72","author":"J P Arab","year":"2020","journal-title":"Hepatology"},{"issue":"04","key":"ref103","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1111\/apt.15335","article-title":"Baseline neutrophil-to-lymphocyte ratio predicts response to corticosteroids and is associated with infection and renal dysfunction in alcoholic hepatitis","volume":"50","author":"E H Forrest","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"issue":"05","key":"ref104","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1053\/j.gastro.2014.01.018","article-title":"A histologic scoring system for prognosis of patients with alcoholic hepatitis","volume":"146","author":"J Altamirano","year":"2014","journal-title":"Gastroenterology"},{"issue":"03","key":"ref105","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1002\/hep.30516","article-title":"Efficacy of granulocyte colony-stimulating factor in the management of steroid-nonresponsive severe alcoholic hepatitis: a double-blind randomized controlled trial","volume":"70","author":"S M Shasthry","year":"2019","journal-title":"Hepatology"},{"issue":"01","key":"ref106","doi-asserted-by":"crossref","first-page":"e0190823","DOI":"10.1371\/journal.pone.0190823","article-title":"Liver transplantation for alcoholic hepatitis: a systematic review with meta-analysis","volume":"13","author":"A Marot","year":"2018","journal-title":"PLoS One"},{"issue":"06","key":"ref107","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1016\/j.jhep.2021.07.033","article-title":"Granulocyte-colony stimulating factor (G-CSF) to treat acute-on-chronic liver failure: a multicenter randomized trial (GRAFT study)","volume":"75","author":"C Engelmann","year":"2021","journal-title":"J Hepatol"},{"issue":"06","key":"ref109","first-page":"1483A","article-title":"Safety and efficacy of DUR-928: a potential new therapy for acute alcoholic hepatitis","volume":"70","author":"T Hassanein","year":"2019","journal-title":"Hepatology"},{"key":"ref110","first-page":"1483","article-title":"DUR-928 therapy for acute alcoholic hepatitis: a pilot study","volume":"70","author":"C J McClain","year":"2019","journal-title":"Hepatology"},{"issue":"02","key":"ref112","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.jhep.2007.03.027","article-title":"A randomized trial of antioxidant therapy alone or with corticosteroids in acute alcoholic hepatitis","volume":"47","author":"S Stewart","year":"2007","journal-title":"J Hepatol"},{"issue":"04","key":"ref113","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1016\/j.jhep.2005.11.039","article-title":"Antioxidants versus corticosteroids in the treatment of severe alcoholic hepatitis \u2013 a randomised clinical trial","volume":"44","author":"M Phillips","year":"2006","journal-title":"J Hepatol"},{"issue":"03","key":"ref114","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1177\/039463200301600304","article-title":"Metadoxine in the treatment of acute and chronic alcoholism: a review","volume":"16","author":"G Addolorato","year":"2003","journal-title":"Int J Immunopathol Pharmacol"},{"issue":"05","key":"ref115","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1053\/j.gastro.2011.09.002","article-title":"Alcoholic liver disease: pathogenesis and new therapeutic targets","volume":"141","author":"B Gao","year":"2011","journal-title":"Gastroenterology"},{"issue":"04","key":"ref116","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1194\/jlr.R119000547","article-title":"Alcohol effects on hepatic lipid metabolism","volume":"61","author":"S Jeon","year":"2020","journal-title":"J Lipid Res"},{"issue":"17","key":"ref117","doi-asserted-by":"crossref","first-page":"95354","DOI":"10.1172\/jci.insight.95354","article-title":"Therapeutic opportunities for alcoholic steatohepatitis and nonalcoholic steatohepatitis: exploiting similarities and differences in pathogenesis","volume":"2","author":"T Greuter","year":"2017","journal-title":"JCI Insight"},{"issue":"05","key":"ref118","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1053\/j.gastro.2020.12.008","article-title":"Integrated multiomics reveals glucose use reprogramming and identifies a novel hexokinase in alcoholic hepatitis","volume":"160","author":"V Massey","year":"2021","journal-title":"Gastroenterology"},{"issue":"05","key":"ref119","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1097\/TP.0b013e31827afb3a","article-title":"Evolving frequency and outcomes of liver transplantation based on etiology of liver disease","volume":"95","author":"A K Singal","year":"2013","journal-title":"Transplantation"},{"issue":"05","key":"ref120","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1002\/hep.25544","article-title":"Outcomes after liver transplantation for alcoholic hepatitis are similar to alcoholic cirrhosis: exploratory analysis from the UNOS database","volume":"55","author":"A K Singal","year":"2012","journal-title":"Hepatology"},{"issue":"03","key":"ref121","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1111\/ajt.13586","article-title":"Early liver transplantation for severe alcoholic hepatitis in the United States \u2013 a single-center experience","volume":"16","author":"G Y Im","year":"2016","journal-title":"Am J Transplant"},{"issue":"05","key":"ref122","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1002\/lt.25448","article-title":"Underestimation of liver transplantation for alcoholic hepatitis in the national transplant database","volume":"25","author":"B P Lee","year":"2019","journal-title":"Liver Transpl"},{"issue":"03","key":"ref123","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1111\/ajt.16143","article-title":"Liver transplantation for alcoholic hepatitis in the United States: excellent outcomes with profound temporal and geographic variation in frequency","volume":"21","author":"T G Cotter","year":"2021","journal-title":"Am J Transplant"},{"issue":"11","key":"ref124","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1002\/lt.24208","article-title":"Liver transplantation for alcoholic hepatitis: a survey of liver transplant centers","volume":"21","author":"M Hasanin","year":"2015","journal-title":"Liver Transpl"},{"key":"ref125","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1136\/bmj.317.7152.172","article-title":"Assessing priorities for allocation of donor liver grafts: survey of public and clinicians","volume":"317","author":"J Neuberger","year":"1998","journal-title":"BMJ"},{"key":"ref126","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1016\/0140-6736(91)90213-9","article-title":"Priority setting: lessons from Oregon","volume":"337","author":"J Dixon","year":"1991","journal-title":"Lancet"},{"issue":"01","key":"ref127","first-page":"40","article-title":"Selection criteria for recipients of scarce donor livers: a public opinion survey in Hong Kong","volume":"12","author":"H M Chan","year":"2006","journal-title":"Hong Kong Med J"},{"key":"ref128","doi-asserted-by":"crossref","first-page":"S65","DOI":"10.1002\/lt.21337","article-title":"Public and professional attitudes to transplanting alcoholic patients","volume":"13","author":"J Neuberger","year":"2007","journal-title":"Liver Transpl"},{"issue":"05","key":"ref129","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/S2468-1253(21)00430-1","article-title":"Early liver transplantation for severe alcohol-related hepatitis not responding to medical treatment: a prospective controlled study","volume":"7","author":"A Louvet","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"}],"container-title":["Seminars in Liver Disease"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/s-0042-1759614.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T00:21:10Z","timestamp":1678494070000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/s-0042-1759614"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,26]]},"references-count":119,"journal-issue":{"issue":"01","published-online":{"date-parts":[[2023,3,10]]},"published-print":{"date-parts":[[2023,2]]}},"URL":"https:\/\/doi.org\/10.1055\/s-0042-1759614","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0272-8087","1098-8971"],"issn-type":[{"value":"0272-8087","type":"print"},{"value":"1098-8971","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,26]]}}}